Lauren Yee
Family Medicine · Montour Falls, NYNPI 1669934204
Payments from drug & device makers
Across 144 payments — averaging $26.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gotham Surgical Solutions & Devices, Inc.$1K
- AstraZeneca$531
- AbbVie$475
- Novo Nordisk$372
- Pfizer$226
- Lilly USA, LLC$188
- plus $792 from 15 others
What the payments were for
- Food & beverage$2,58468%
- Education$1,20032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gotham Surgical Solutions & Devices, Inc. | 1 | $1,200 |
| AstraZeneca | 30 | $531 |
| AbbVie | 21 | $475 |
| Novo Nordisk | 21 | $372 |
| Pfizer | 14 | $226 |
| Lilly USA, LLC | 14 | $188 |
| Exact Sciences | 8 | $155 |
| Boehringer Ingelheim | 6 | $118 |
| Amgen | 6 | $106 |
| Johnson & Johnson | 4 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| Merck | 2 | $56 |
| GSK | 3 | $50 |
| Novartis | 2 | $39 |
| Corcept Therapeutics | 2 | $29 |
| Biogen | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Bayer | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$3,784 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $47,456 |
| EliquisApixaban | 36 | $35,963 |
| XareltoRivaroxaban | 21 | $25,502 |
| JardianceEmpagliflozin | 18 | $24,969 |
| RybelsusSemaglutide | 20 | $22,543 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $20,547 |
| FarxigaDapagliflozin Propanediol | 13 | $19,821 |
| MounjaroTirzepatide | 11 | $12,291 |
| Levothyroxine Sodium | 93 | $2,490 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,470 |
| Valsartan | 40 | $2,250 |
| Atorvastatin Calcium | 88 | $1,310 |
| Telmisartan | 23 | $1,287 |
| Gabapentin | 60 | $1,263 |
| Metronidazole | 11 | $1,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $372 | $69,99962 claims |
| PfizerEliquis | $226 | $35,96336 claims |
| Johnson & JohnsonXarelto | $71 | $25,50221 claims |
| Boehringer IngelheimJardiance | $118 | $24,96918 claims |
| AstraZenecaFarxiga, Symbicort | $531 | $22,29024 claims |
| GSKTrelegy Ellipta | $50 | $20,54718 claims |
| Lilly USA, LLCMounjaro | $188 | $12,29111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Montour Falls
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.